HUMAN ANTI INFLIXIMAB

Human anti Infliximab, clone AbD19370_hIgG1, is an anti-idiotypic antibody that specifically recognizes free infliximab monoclonal antibody and infliximab when bound to its target, Tumor Necrosis Factor Alpha (TNFα). It can be used in bioanalytical assays to measure the levels of infliximab and biosimilar products, such as Inflectra and Renflexis, in patient samples.Human anti Infliximab, clone AbD19370_hIgG1 is not paratope-specific and is non-inhibitory; it binds to an epitope outside the infliximab binding site. This epitope is shared with other chimeric antibodies that are highly homologous to infliximab including the chimeric antibody cetuximab, but not rituximab. The antibody can be used as a detection antibody in a pharmacokinetic (PK) assay in the bridging format to measure total drug (free, partially bound and fully bound). As it is a fully human antibody, it can also be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera.Infliximab (branded as Remicade®) is a chimeric monoclonal antibody drug (IgG1/kappa) that has been approved for treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. It is directed against TNFα and acts by blocking the binding of this cytokine to its receptors. Infliximab also induces apoptosis of TNFα expressing T-lymphocytes.View a summary of all anti-infliximab antibodies.

• Clonality: Monoclonal
• Host: Human
• Isotype: IgG1

• Quantity: 0.1 mg
• Storage: +4ºC, -20ºC if preferred
• Buffer: Phosphate buffered saline, 0.01% Thiomersal

• ELISA (ELISA)